Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trial
Win ratio analysis of the NOAH-AFNET 6 trial reveals no advantage of anticoagulation in stroke risk reduction for patients with device-detected atrial fibrillation.
Key Points
The win ratio showed no significant advantage of edoxaban over no anticoagulation in preventing adverse events.
From 2534 participants, the win ratio comparing edoxaban to no anticoagulation was 0.87, suggesting no clear benefit.
Death and major bleeding were the most common outcomes, with a high percentage of undecided comparisons at 84.9%.
This analysis challenges the perceived benefits of anticoagulation therapy in patients with device-detected atrial fibrillation.